Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 10/20 | 0.83 |
| ▸ | DRD4 | P21917 | 9/20 | 0.48 |
| ▸ | DRD2 | P14416 | 7/20 | 0.48 |
| ▸ | DRD3 | P35462 | 6/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12185580 | 0.91 | PRCP (1.00) | PRCPDRD4DRD2DRD3CYP1A2 | |
| SCHEMBL14701322 | 0.90 | PRCP (0.68) | PRCPDRD4DRD2DRD3CYP1A2 | |
| SCHEMBL14686540 | 0.90 | PRCP (0.83) | PRCPDRD4DRD2DRD3 | |
| SCHEMBL14701320 | 0.89 | PRCP (0.66) | PRCPDRD4DRD2DRD3CYP1A2 | |
| SCHEMBL14701323 | 0.82 | PRCP (0.84) | PRCPMEN1KMT2A | |
| SCHEMBL12185552 | 0.81 | PRCP (0.82) | PRCPDRD4DRD2DRD3CYP1A2 | |
| SCHEMBL14701324 | 0.81 | PRCP (0.66) | PRCPDRD4DRD2DRD3TSHR | |
| SCHEMBL14749289 | 0.81 | PRCP (0.56) | PRCPDRD4DRD2DRD3ALDH1A1 | |
| SCHEMBL14691670 | 0.81 | PRCP (0.69) | PRCPDRD4DRD2DRD3ACHE | |
| SCHEMBL12185590 | 0.80 | PRCP (0.68) | PRCPDRD4DRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9365539-B2 | Prolylcarboxypeptidase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-06-14 | — | — | US | disclosed |
| US-20130040929-A1 | NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2013-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130040929-A1 | NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS | PRCP, PREP, ENPEP | PRCP 1/4885DRD4 4740/4885DRD2 4864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.